Nature Communications (May 2024)

Prodrug-conjugated tumor-seeking commensals for targeted cancer therapy

  • Haosheng Shen,
  • Changyu Zhang,
  • Shengjie Li,
  • Yuanmei Liang,
  • Li Ting Lee,
  • Nikhil Aggarwal,
  • Kwok Soon Wun,
  • Jing Liu,
  • Saravanan Prabhu Nadarajan,
  • Cheng Weng,
  • Hua Ling,
  • Joshua K. Tay,
  • De Yun Wang,
  • Shao Q. Yao,
  • In Young Hwang,
  • Yung Seng Lee,
  • Matthew Wook Chang

DOI
https://doi.org/10.1038/s41467-024-48661-y
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Prodrugs have been explored as an alternative to conventional chemotherapy; however, their target specificity remains limited. The tumor microenvironment harbors a range of microorganisms that potentially serve as tumor-targeting vectors for delivering prodrugs. In this study, we harness bacteria-cancer interactions native to the tumor microbiome to achieve high target specificity for prodrug delivery. We identify an oral commensal strain of Lactobacillus plantarum with an intrinsic cancer-binding mechanism and engineer the strain to enable the surface loading of anticancer prodrugs, with nasopharyngeal carcinoma (NPC) as a model cancer. The engineered commensals show specific binding to NPC via OppA-mediated recognition of surface heparan sulfate, and the loaded prodrugs are activated by tumor-associated biosignals to release SN-38, a chemotherapy compound, near NPC. In vitro experiments demonstrate that the prodrug-loaded microbes significantly increase the potency of SN-38 against NPC cell lines, up to 10-fold. In a mouse xenograft model, intravenous injection of the engineered L. plantarum leads to bacterial colonization in NPC tumors and a 67% inhibition in tumor growth, enhancing the efficacy of SN-38 by 54%.